Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.
Also called NCT05557942
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 186 participants
- Sponsor
- Aerovate Therapeutics
- Registry
-
NCT05557942
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Latvia, Mexico, Poland, Portugal, Singapore, South Africa, Spain, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05557942. Randomized; quadruple masking; primary purpose treatment. Start 2022-11-02 (actual); primary completion 2024-08-08 (actual). Results posted on 2024-10-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
- Acronym
- IMPAHCT-FUL
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- AV-101
- Lead sponsor
- Aerovate Therapeutics
Record details
- Record id
cardio:ct-nct05557942- Content hash
b5e4573770d0ac2c640e0b55d991c22e17d9a80d9820c66de3ced1a00bd391d2